Inhibition of human thrombin by the constituents of licorice: inhibition kinetics and mechanistic insights through in vitro and in silico studies. Issue 7 (22nd January 2020)

• Record Type: Journal Article
• Authors: Shi, Cheng-Cheng; Chen, Tian-Ran; Zhang, Qi-Hua; Wei, Ling-Hua; Huang, Chao; Zhu, Ya-Di; Liu, Hai-Bin; Bai, Ya-Kun; Wang, Fang-Jun; Guo, Wen-Zhi; Zhang, Li-Rong; Ge, Guang-Bo
• Is Part Of: RSC advances. Volume 10:Issue 7(2020)
• Page Start: 3626
• Page End: 3635
• Publication Date: 2020-01-22
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/c9ra09203j
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : Licochalcone A, a bioactive compound from licorice, displayed strong inhibition of thrombin. Abstract : Thrombin inhibition therapy is a practical strategy to reduce thrombotic and cardiovascular risks via blocking the formation of blood clots. This study aimed to identify naturally occurring thrombin inhibitors from licorice (one of the most popular edible herbs), as well as to investigate their inhibitory mechanisms. Among all tested licorice constituents, licochalcone A was found as the most efficacious agent against human thrombin (IC50 = 7.96 μM). Inhibition kinetic analyses demonstrated that licochalcone A was a mixed inhibitor against thrombin-mediated Z -Gly-Gly-Arg-AMC acetate hydrolysis, with a K i value of 12.23 μM. Furthermore, mass spectrometry-based chemoproteomic assays and molecular docking simulations revealed that licochalcone A could bind to human thrombin at both exosite I and the catalytic site. In summary, our findings demonstrated that the chalcones isolated from licorice were a new class of direct thrombin inhibitors, also suggesting that licochalcone A was a promising lead compound for developing novel anti-thrombotic agents.